31.1 C
Vientiane
Wednesday, July 9, 2025
spot_img
Home Blog Page 436

ZTO Files Annual Report on Form 20-F for Fiscal Year 2024

SHANGHAI, April 17, 2025 /PRNewswire/ — ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057), a leading and fast-growing express delivery company in China (“ZTO” or the “Company”), today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on April 17, 2025. The annual report on Form 20-F can be accessed on the Company’s investor relations website at http://zto.investorroom.com as well as the SEC’s website at http://www.sec.gov.

The Company will provide a hard copy of its annual report on Form 20-F containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company’s IR Department at ir@zto.com.

The Company has also today published its annual report for the fiscal year ended December 31, 2024 pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“SEHK”), which can be accessed on the Company’s investor relations website at http://zto.investorroom.com as well as the SEHK’s website at http://www.hkexnews.hk.

About ZTO Express (Cayman) Inc.

ZTO is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China.

ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain.

For more information, please visit http://zto.investorroom.com.

For investor and media inquiries, please contact:

ZTO Express (Cayman) Inc.

Investor Relations

E-mail: ir@zto.com
Phone: +86 21 5980 4508

Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum’s Disease at World Orphan Drug Congress USA 2025

  • CBL-514, Caliway’s novel small molecule drug, was selected for data presentation at the World Orphan Drug Congress USA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum’s Disease Treatment.
  • The Phase 2 topline results met all primary and secondary endpoints, with 64.5% of painful lipomas showing ≥ 50% dimension reduction or complete clearance (per-protocol population), and pain being reduced by 4.7 points (on a 10-point scale).
  • The program has advanced to a U.S. FDA-approved Phase 2b study (CBL-0202DD), with subject recruitment expected to be completed by Q3 2025, representing a potential breakthrough for patients with no approved treatment options.

TAIPEI, April 17, 2025 /PRNewswire/ — Caliway Biopharmaceuticals (TWSE: 6919) announced today that it has been invited to present the clinical results of its CBL-514 Phase 2 study (CBL-0201DD) in Dercum’s Disease at the upcoming World Orphan Drug Congress USA 2025, to be held in Boston on April 24, 2025.

CBL-514 is a novel 505(b)(1) small-molecule drug developed by Caliway. It has previously demonstrated promising results in the field of medical aesthetics. CBL-514 is also being investigated for Dercum’s Disease— a rare disease characterized by the growth of painful lipomas, with no approved treatment to date.

According to the CBL-0201DD Phase 2 study results, 64.5% of painful lipomas showed dimensions reduction of more than 50% or complete clearance after CBL-514 treatments, with more than half of painful lipomas achieved this outcome after only one CBL-514 treatment. The pain score was also reduced by 4.7 points (out of 10).

These results support CBL-514’s potential as a first-in-class treatment for Dercum’s disease, offering new hope to patients by significantly reducing lipoma size and pain.

The World Orphan Drug Congress USA is a leading global conference focused on rare disease and orphan drug development. Bringing together over 2,000 participants from academia, regulatory agencies, pharmaceutical and biotech companies, patient advocacy groups, and investors. The event serves as a key platform for advancing scientific innovation, regulatory policies, and access strategies in rare disease therapies.

Being selected to present at the most important event for all rare disease stakeholders, not only highlights the clinical potential of CBL-514 in rare disease treatment, but also underscores Caliway’s ongoing commitment to addressing unmet medical needs.

The drug has entered a U.S. FDA-approved Phase 2b clinical study (CBL-0202DD), which is currently ongoing and expected to complete patient recruitment by Q3 2025. If successful, CBL-514 could become the first approved treatment for Dercum’s Disease, offering a long-awaited therapeutic option for patients worldwide.

CBL-514 Study Presentation Info at World Orphan Drug Congress USA:

  • Conference: World Orphan Drug Congress USA 2025
  • Date & Time: April 24, 2025 (Thursday), 10:40 AM (Eastern Time)
  • Presentation Title: Efficacy and Safety of CBL-514, a Novel Lipolytic Injectable, in the Treatment of Dercum’s Disease: Phase 2 Study Results
  • Location: Boston Convention & Exhibition Center | Theater 2 – Hall C

For more details on the World Orphan Drug Congress USA 2025, please visit: the official website.

About Dercum’s Disease

Dercum’s disease is a rare disorder characterized by the development of painful lipomas primarily located on the trunk region, and the extremities close to the trunk. The pain is chronic (>3 months), symmetrical, often disabling, and resistant to traditional analgesics.

The etiology of Dercum’s disease remains unknown. There is no approved drug nor recommended standard treatment for Dercum’s disease yet. The current treatment options, including surgical removal, liposuction, electrotherapy, and inflammation inhibitors, are symptomatic, and the efficacies are limited with numerous adverse events. The clinical need for Dercum’s disease remains unmet.

According to the Global Dercum’s Disease Market Research Report, the global Dercum’s disease treatment market size in 2022 was $11.8 billion. With a compound annual growth rate (CAGR) of 6.76%, the global market of Dercum’s disease treatment in 2032 is estimated to expand to $22.7 billion.

About CBL-514

CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world’s first injectable lipolysis drug that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas without causing any systematic side effects on the central nervous system, cardiovascular system, and respiratory system. CBL-514 has demonstrated fewer side effects, superior efficacy, and fewer required treatments compared with existing surgical procedures and other non-invasive localized fat reduction solutions.

Caliway is currently investigating multiple indications for CBL-514, including non-surgical fat reduction, moderate-to-severe cellulite and weight rebound management. A derivative compound, CBL-514D, is being developed for indications including rare diseases such as Dercum’s disease and Obstructive Sleep Apnea (OSA). As of the end of November 2024, Caliway has enrolled a total of 520 subjects in clinical studies related to CBL-514. To date, 10 clinical studies have been completed with results available, and all these studies have met their primary efficacy endpoints and safety parameters. CBL-514 has demonstrated precise efficacy with a favorable safety profile across multiple indications, showing outstanding statistical significance (p<0.00001 or p<0.0001) in both ITT and FAS populations. Caliway plans to initiate subject recruitment for two pivotal global Phase 3 studies for localized fat reduction in the second half of 2025.

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the Taiwan Exchange (TWSE-6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. For more information, please visit: https://www.caliway.com.tw/en

Disclaimer

This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.

Vipshop Filed 2024 Annual Report on Form 20-F

GUANGZHOU, China, April 17, 2025 /PRNewswire/ — Vipshop Holdings Limited (NYSE: VIPS), a leading online discount retailer for brands in China (“Vipshop” or the “Company”), today announced that the Company has filed its annual report on Form 20-F that includes its audited financial statements for three years ended December 31, 2024 with the U.S. Securities and Exchange Commission on April 17, 2025. The annual report is available on the Company’s website at ir.vip.com. Holders of the Company’s securities may request a copy of the Company’s annual report free of charge according to the instructions provided on the Company’s website.

About Vipshop Holdings Limited

Vipshop Holdings Limited is a leading online discount retailer for brands in China. Vipshop offers high quality and popular branded products to consumers throughout China at a significant discount to retail prices. Since it was founded in August 2008, the Company has rapidly built a sizeable and growing base of customers and brand partners. For more information, please visit https://ir.vip.com/.

Investor Relations Contact

Tel: +86 (20) 2233-0732
Email: IR@Vipshop.com 

 

HIKSEMI Unveils GEN5 SSD and Immersive Storage Solutions at the 137th Canton Fair

GUANGZHOU, China, April 17, 2025 /PRNewswire/ — HIKSEMI made a striking debut at the 137th Canton Fair, held from April 15th to 19th. Under the theme “Innovations Beyond Storage”, HIKSEMI showcased how cutting-edge technologies like PCIe 5.0 are breaking through traditional storage limitations to deliver faster, larger, and more powerful solutions that enhance everyday life and empower greater efficiency.


The highlight of the exhibition was the launch of the GEN5 SSD series, which boasts an impressive read speed of up to 14,500MB/s—twice that of the GEN4 SSD. This groundbreaking product has garnered significant attention for its ability to meet the demanding performance needs of applications such as gaming, entertainment, and content creation.


HIKSEMI curated seven immersive zones, blending technology into daily life and industry operations. Visitors explored intelligent document systems, cloud backup solutions, ultra-fast SSDs and DDR for 8K gaming, and professional-grade memory cards and portable drives designed for outdoor photography. Industrial showcases included secure data handling, stable storage for data centers, and high-concurrency processing for smart vehicles.

HIKSEMI introduced its branded IP mascot, Semi Elephant, to enhance audience interaction and engagement. Inspired by the saying that an elephant never forgets, the Semi Elephant symbolizes reliability, vast capacity, and enduring memory, highlighting HIKSEMI’s technical excellence while fostering emotional connections with consumers from diverse backgrounds.

Looking ahead, HIKSEMI remains committed to advancing storage technology, developing innovations, and expanding applications to enhance global user experiences.

OSL Powers Staking and Custody for ChinaAMC (HK)’s First Staking-Enabled Ether ETF

HONG KONG, April 17, 2025 /PRNewswire/ — OSL Digital Securities (OSL), a leading regulated digital asset platform and a member of OSL Group (863.HK), will provide staking services for the Ether assets of China Asset Management (Hong Kong)’s (ChinaAMC (HK)) Ether ETF (3046.HK / 83046.HK / 9046.HK), following formal approval from the Securities and Futures Commission of Hong Kong (SFC). Pioneering staking-as-a-service in a highly regulated environment, staking of ChinaAMC (HK)’s Ether assets via OSL may commence on 15 May 2025.

This is a groundbreaking evolution in the regulated digital asset landscape, enabling investors to participate in the Ethereum blockchain protocol’s proof-of-stake rewards mechanism through a tightly regulated and transparent platform. Staking of the ETF’s underlying Ether assets transforms the ETF from a passive investment product into an active participant in the Ethereum ecosystem while maintaining rigorous compliance standards.

Eugene Cheung, Chief Commercial Officer of OSL, emphasised the strategic importance of this milestone, “This landmark represents the maturing of crypto assets into an institutional-grade yield-generating product. As the regulated infrastructure provider enabling this functionality, OSL is proud to facilitate secure access to Ethereum’s native staking rewards while meeting the highest standards of investor protection. This achievement underscores Hong Kong’s leadership in developing sophisticated digital asset frameworks that bridge traditional and decentralised finance.”

Thomas Zhu, Head of Digital Assets and Family Office Business, ChinaAMC (HK), said, “Our collaboration with OSL to bring Ethereum staking capabilities to the ChinaAMC Ether ETF creates a secure, regulated gateway for investors of all types. By simplifying access to ETH staking, this service significantly lowers the threshold to participating in Ethereum staking, allowing both institutional and retail investors to easily contribute to network security while earning rewards. It also supports the broader growth of decentralized finance (DeFi), marking an important step forward for blockchain adoption in a regulated market.”

ChinaAMC (HK)’s Ether ETF, launched in April 2024 as part of Hong Kong’s first wave of spot crypto ETFs, with BOCI Prudential, serving as the primary custodian and fund administrator of the fund. OSL’s appointment as a staking infrastructure provider leverages the company’s comprehensive regulatory credentials, built upon OSL’s recent partnership with Kiln, the leading enterprise-grade staking platform. By combining Kiln’s institutional staking technology with OSL’s SFC-licensed platform, the collaboration delivers a fully compliant staking solution that meets the exacting requirements of ETF providers and institutional investors.

About OSL Hong Kong

As a subsidiary of the publicly listed OSL Group (HKEX: 863.HK), OSL Digital Securities is Hong Kong’s first and most established SFC-licensed and insured digital asset platform. Operating since 2018, the platform provides institutional-grade digital asset services to corporations, financial institutions, professional and retail investors.

OSL Hong Kong delivers services across five core domains: OTC brokerage, Omnibus broker solutions, custody, wealth management, and retail services. The OTC brokerage services provide 24/7 high-liquidity crypto trading with fiat on/off-ramp services. Custody solutions feature client-asset segregated wallet management backed by US$1 billion insurance coverage. The wealth management suite offers crypto investments to traditional investors, including tokenised treasuries, RWAs, structured crypto products, and quant investment strategies. Retail services bring institution-grade security and crypto access to professional and retail investors.

As a pioneer in bridging traditional finance and the digital asset economy, OSL Group adheres to its core concept:  Open, Secure, and Licensed, empowering the next generation of global financial infrastructure. In addition to Hong Kong (SAR), OSL Group expands operations under full regulatory compliance in Japan, Australia, Europe and beyond.

For more information, visit osl.com.

VinFast partners with Bengkel BOS to expand service workshop network in Indonesia


HANOI, VIETNAM – Media OutReach Newswire – 17 April 2025 – VinFast has announced a new partnership with PT Penta Artha Impressi (Bengkel BOS), an Indonesian service provider, aimed at improving customer service and maximizing benefits for those transitioning to electric vehicles. This move is part of VinFast’s strategy to expand its sales and after-sales network as its electric vehicle product line grows in Indonesia.

Mr. Mochamad Agus Rijadi (left), Director of Aftersales at VinFast Indonesia, and Mr. Endro Arifin, President Director of PT Penta Artha Impressi (Bengkel BOS), at the MOU signing ceremony.
Mr. Mochamad Agus Rijadi (left), Director of Aftersales at VinFast Indonesia, and Mr. Endro Arifin, President Director of PT Penta Artha Impressi (Bengkel BOS), at the MOU signing ceremony.

Under the agreement, 12 service workshops of PT Penta Artha Impressi (Bengkel BOS) will be authorized to provide repair, warranty, and maintenance services for VinFast’s electric vehicle models. This network of service workshops is strategically located across key areas such as South Jakarta, West Jakarta, East Jakarta, Tangerang, and Yogyakarta, aiming to maximize convenience for customers.

The maintenance, repair, and warranty services provided by Bengkel BOS will conform to VinFast’s quality standards and procedures. This network of service centers is fully equipped with modern facilities, machinery, and equipment, meeting strict technical requirements.

As a strategic authorized service partner, Bengkel BOS will also distribute genuine VinFast parts and components, ensuring that electric vehicle users in Indonesia have access to high-quality products that adhere to VinFast’s global standards.

Throughout the partnership, VinFast is committed to providing personnel training and technical advisory support to Bengkel BOS. This is particularly crucial as VinFast’s electric vehicle product line expands in Indonesia and the number of vehicle deliveries is projected to increase.

Mr. Endro Arifin, President Director at PT Penta Artha Impressi (Bengkel BOS), stated: “Leveraging our experience, local expertise, and extensive service workshop network, we are honored to become a strategic partner of VinFast on its journey to conquer the Indonesian market. Together, Bengkel BOS and VinFast are committed to delivering exceptional experiences to consumers while contributing to the continuous development of the region’s electric vehicle market.”

Mr. Pham Sanh Chau, CEO of VinFast Asia, stated, To accelerate the green transition in Indonesia, we believe that building strong, long-term customer trust is paramount. To achieve this, VinFast actively collaborates with reputable partners to expand our network of authorized service workshops in Indonesia. We remain steadfast in our commitment to the three core pillars that have defined the VinFast brand: high-quality products, inclusive pricing, and outstanding after-sales service.

VinFast offers one of the market’s most diverse portfolios of all-electric vehicles, ranging from the mini-SUV VF 3 and the A-segment SUV VF 5 to the C-segment SUV VF e34. In parallel with its continuously expanding product ecosystem, VinFast is broadening its network of dealerships and service workshops nationwide, aiming to deliver high-quality products and services to consumers.

Concurrently, VinFast is cultivating a comprehensive green mobility ecosystem through strategic collaborations with key partners, including the all-electric taxi operator GSM and the global charging infrastructure developer V-GREEN.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

About VinFast

VinFast (NASDAQ: VFS), a subsidiary of Vingroup JSC, one of Vietnam’s largest conglomerates, is a pure-play electric vehicle (“EV”) manufacturer with the mission of making EVs accessible to everyone. VinFast’s product lineup today includes a wide range of electric SUVs, e-scooters, and e-buses. VinFast is currently embarking on its next growth phase through rapid expansion of its distribution and dealership network globally and increasing its manufacturing capacities with a focus on key markets across North America, Europe and Asia. Learn more at

About PT Penta Artha Impressi (Bengkel BOS)

Bengkel BOS operates 29 high-standard car workshops, prioritizing its business in tyres, oils, spare parts, and car services. In addition, the services are supported by professional technicians and the latest technology. Bengkel BOS is committed to providing excellent service for customers and becoming a leading network of digital automotive workshops. Learn more at:

MEXC Ventures Launches IgniteX: A $30 Million Initiative to Foster Web3 Talent and Innovation

VICTORIA, Seychelles, April 17, 2025 /PRNewswire/ — MEXC Ventures, the investment arm of the globally leading cryptocurrency exchange MEXC, has announced a $30 million allocation to support Web3 talent and accelerate innovation across the decentralized ecosystem. The investment initiative foresees a 5-year span and is part of the broader Corporate Social Responsibility effort by MEXC Ventures, “IgniteX,” in line with its global strategy of fostering sustainable blockchains through support and empowerment of young talents.

MEXC Ventures Launches IgniteX: A $30 Million Initiative to Foster Web3 Talent and Innovation
MEXC Ventures Launches IgniteX: A $30 Million Initiative to Foster Web3 Talent and Innovation

The purpose of the initiative undertaken by MEXC Ventures is to create a launchpad program that will serve as a hotbed for talent nurturing and idea development. The collaboration with Korea University’s Blockchain Research Institute will mark the beginning of the “IgniteX” initiative, with more details to be unveiled in an upcoming official announcement. MEXC will work closely with the institute on blockchain development, academic exchanges, and talent cultivation. MEXC Ventures encourages submissions from early-stage Web3 startups, research initiatives, developer communities, and academic institutions working on decentralized infrastructure, AI-integrated blockchain solutions, stablecoins, and fintech tools. MEXC Ventures aims to include mentorship, educational efforts, and funding as part of the program to create a future-ready blockchain ecosystem, thus ensuring a smooth transition for the next generation of users into Web3 and preparing a willing, enthusiastic, and well-trained pool of leaders to develop it further.

The impact-driven campaign will entail a comprehensive and multi-pronged approach that includes several key elements. The foundation will be the $30 million pledge, which will serve to fund education, project support, and development initiatives. The second part of the campaign will focus on organizing hackathons and developer engagement programs in the form of global events to identify and support emerging talents.

Education will form a major part of the campaign, with university scholarships and blockchain courses offered through partnerships with academic institutions. This step is crucial to making blockchain technologies and the underlying coding and programming languages more accessible to a greater number of potential developers and IT students. Mentorship programs will be launched in tandem to make sure talents have access to adequate training, event participation, and the experience of current Web3 leaders.

Lastly, strategic sector support will be implemented to ensure that funding is provided to promising projects. Special focus will be placed on initiatives developing stablecoins, AI-based solutions, and blockchain infrastructure elements.

As a CSR initiative, “IgniteX” adheres to achieving strategic objectives, which are based on building a pipeline of high-potential Web3 startups with early MEXC involvement for future cultivation and capitalization. This will have a positive impact on brand recognition for MEXC and position it as a strategic and valuable contributor to the development of Web3 space. The campaign will also help foster cross-border collaboration among all participants of the blockchain sector and promote diversity and inclusion based on shared blockchain values.

Through “IgniteX”, MEXC Ventures aims to create an impact on the global Web3 ecosystem by empowering potential future leaders and developers through education and responsible mentorship.

About MEXC Ventures

MEXC Ventures is a comprehensive fund under MEXC dedicated to driving innovation in the cryptocurrency sector through investments in L1/L2 ecosystems, strategic investments, M&A, and incubation. Upholding the principle of “Empowering Growth Through Synergy,” MEXC Ventures is committed to supporting innovative ideas and active builders in crypto.

MEXC Ventures is an investor and supporter of TON and Aptos, and looks forward to staying at the forefront of TON and Aptos innovations while actively engaging with builders to drive ecosystem growth.

For more information, visit: MEXC Ventures Website

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases

MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ — Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to two bispecific antibodies, HXN-1002 and HXN-1003, both utilizing Earendil Labs’ proprietary AI and high-throughput discovery & research platform. This transaction is subject to customary closing conditions.

As part of the agreement:

  • Earendil Labs will receive an upfront payment of $125 million.
  • Earendil Labs is eligible to receive up to a total of $1.72 billion in development and commercial milestone payments, including a $50 million near-term payment.
  • Earendil Labs is eligible to receive tiered royalties on product sales ranging from the high-single to low-double digits.

“We are thrilled to collaborate with Sanofi, a global leader in immunology, to advance the development of two bispecifics, HXN-1002 and HXN-1003, for autoimmune and inflammatory bowel diseases,” said Jian Peng, PhD, CEO of Earendil Labs, “Our platform leverages state-of-the-art predictive protein modeling and high-throughput biology, revolutionizing the discovery and development of bispecific antibodies. This collaboration underscores Earendil Labs’ capability to generate potential first-in-class or best-in-class product candidates, with the aim of transforming patient care.”

Zhenping Zhu, MD, PhD, President & co-CEO of Earendil Labs, added: “Autoimmune diseases, which affect multi-millions of patients, are characterized by chronic disease process and high relapse rates. These diseases often require life-long treatment, severely impacting patients’ quality of life and significantly increasing the societal burden. Though multiple agents have been approved for clinical treatment, their efficacy often remains limited, highlighting significant unmet medical needs. We firmly believe that Sanofi’s extensive expertise in the autoimmune disease field will significantly accelerate the development of HXN-1002 and HXN-1003, ultimately bringing these potentially life-changing treatments to patients worldwide as soon as possible.”

About Earendil LabsEarendil Labs is a US-based biotech company redefining biopharmaceutical innovation with its cutting-edge AI-powered platform. By combining advanced machine learning, generative protein engineering, and high-throughput experimental techniques, Earendil Labs and its affiliate Helixon Therapeutics streamline drug discovery & research process with aim of significantly accelerating drug development. Earendil Labs’ proprietary integrated framework enables precise optimization of functionality, manufacturability, and developability of protein-based biologics with first-in-class or best-in-class potential.

About HXN-1002: HXN-1002 is a bispecific antibody targeting both α4β7 and TL1A. By simultaneously inhibiting two clinically validated targets, HXN-1002 holds great potential to significantly improve clinical efficacy, particularly for the refractory patients. It is designed to provide a treatment option for patients with moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD).

About HXN-1003: HXN-1003 targets TL1A and IL23, two central drivers of inflammation in various human autoimmune diseases. By simultaneously blocking both pathways, the bispecific antibody has shown synergistic efficacy in preclinical models of colitis and skin inflammation, with great potential to address unmet needs in patients refractory to currently existing therapies.